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Abstract 
The incidence of colorectal cancer (CRC) is increasing worldwide. CRC has high mortality when 
detected at advanced stages, yet it is also highly preventable. Given the difficulties in implementing 
major lifestyle changes or widespread primary prevention strategies to decrease CRC risk, screening 
is the most powerful public health tool to reduce mortality. Screening methods are effective but have 
limitations. Furthermore, many screen-eligible persons remain unscreened. We discuss established 
and emerging screening methods, and potential strategies to address current limitations in CRC 
screening. A quantum step in CRC prevention might come with the development of new screening 
strategies, but great gains can be made by deploying the available CRC screening modalities in ways 
that optimize outcomes while making judicious use of resources. 
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Screening can greatly reduce colorectal cancer (CRC) incidence and mortality. So, have we solved 
the CRC problem? The increasing incidence of CRC worldwide and in younger persons indicates 
that many challenges remain. Screening has not eliminated CRC. Primary prevention is difficult, so 
CRC control efforts rely largely on screening. Approximately one-third of screen-eligible Americans 
have not been screened;1 an estimated 46%–63% of deaths from CRC in the United States (US) have 
been attributed to missed screening opportunities.2 Therefore, the effectiveness of a screening 
strategy depends not only on screening test performance characteristics, but also on patient 
adherence. The burden of CRC might be further reduced with successful deployment of the 
screening strategies we already have, which we know work, as well as innovations in screening 
methods or risk stratification and personalized screening.  
 
Screening Strategies 
Although CRC is the second leading cause of cancer death in the US, CRC incidence and 
mortality have been decreasing substantially over the past several decades.3 It is estimated that 
much of this reduction can be attributed to screening4 with removal of precancerous polyps and 
detection of early stage CRC.5  
CRC is the only cancer for which screening has been proven to reduce cancer mortality in 
average-risk women and average-risk men. Several screening tests are available, each with 
strengths and limitations. The quality of evidence to support these screening tests varies. 
Randomized controlled trials have found significant reductions in CRC mortality among patients 
screened by guaiac-based fecal occult blood tests (gFOBTs) or flexible sigmoidoscopy, whereas 
observational studies support the effects of fecal immunochemical tests (FITs) and screening 
colonoscopies in reducing deaths. Data are available from only cross-sectional studies of the 
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effects of multi-target stool DNA (mt-sDNA) test and computed tomography colonography 
(CTC), comparing performance characteristics with those of colonoscopy. There have been no 
head to head studies to demonstrate that any one test is superior to another for reducing CRC 
mortality or incidence. 
 
Stool-based tests  
The gFOBT uses the pseudoperoxidase activity of heme to detect the presence of blood in stool. 
Dietary modification and avoidance of non-steroidal anti-inflammatory drugs and vitamin C are 
recommended to avoid false-positive and false-negative results, respectively.6 Test takers are 
asked to collect 3 stool samples for each screening round. Data from 5 randomized controlled 
trials, comprising more than 440,000 participants with 11–30 years of follow up, support the 
efficacy of this test.  
Screening with gFOBTs every 2 years (biennially) reduced CRC mortality by 9%–22% 
over 2–9 rounds of screening (Table 1).7-12 In a study that directly compared annual or biennial 
gFOBTs to usual care in the US, annual screening resulted in a greater reduction in CRC 
mortality than biennial screening over 30 years (32% vs 22%).9 CRC incidence was reduced by 
20% with annual screening vs 17% with biennial screening over 18 years of follow-up.13 There 
were greater reductions in CRC-specific mortality among men than women in some studies.9 The 
gFOBT used in these studies (Hemoccult II) detects CRC with lower levels of sensitivity than 
available gFOBTs (which detect CRC with 62%–79% sensitivity and of 87%–96% specificity) 
(Table 2).14, 15  
The FIT has largely replaced gFOBT due to the relative advantages of the FIT, which 
uses an antibody to detect human globin and is therefore not affected by diet. Only 1 stool 
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sample is required for many available FITs, and studies have demonstrated significantly greater 
adherence to FIT than the gFOBT.16 There have been no randomized controlled studies of the 
effectiveness of FIT in reducing CRC mortality or incidence. However, a study that examined 
staggered initiation of biennial FIT screening across regions in Italy found a 22% reduction in 
CRC mortality in regions that offered FIT early compared with regions that delayed FIT 
screening (Table 1).17 Observational cohort studies reported a 10% reduction in CRC incidence18 
and a 62% reduction in CRC mortality attributable to FIT.19 A meta-analysis of test characteristic 
studies reported that FIT detected CRC with a pooled sensitivity of 79% and specificity of 94% 
(Table 2).20 These studies are based on 1-time application compared with colonoscopy and do 
not account for potential detection of neoplasia on future rounds of screening. Based upon 
superior test characteristics, lack of need for dietary or medication modification, and greater 
adherence, annual FIT is recommended over gFOBT.21  
CRC is associated with genetic and epigenetic changes.22 CRC cells are shed into the 
stool, and their DNA alterations can be detected. However, the CRC cell DNA must be 
distinguished from bacterial DNA, which is much more abundant. The mt-sDNA test combines a 
FIT with assays for abnormally methylated regions of DNA associated with colorectal 
carcinogenesis.23 Subjects taking the test are not required to have any dietary or medication 
modifications, though test completion requires mailing of a test kit to the subject, who must then 
return a FIT and stool sample in buffer. Navigators, supplied by the manufacturer, help improve 
adherence.  
There have been no randomized controlled studies of the effects of mt-sDNA test on 
CRC mortality and incidence. A study compared results of 1-time use of mt-sDNA vs FIT in 
9989 average-risk adults who underwent colonoscopy as the reference standard. The mt-sDNA 
 7 
test detected CRC and advanced adenoma with 92.3% sensitivity, vs 73.8% sensitivity for the 
FIT, but with only 86.6% specificity, compared with 94.9% for the FIT (Table 2).23 The mt-
sDNA test detected sessile serrated polyps ≥10 mm with 42.4% sensitivity compared with 5.1% 
sensitivity for the FIT. There are limited data on the appropriate surveillance interval, though the 
manufacturer recommends screening every 3 years. It is not clear how to manage patients with 
abnormal results from the mt-sDNA test but normal results from colonoscopy. 
 
Direct visualization 
Flexible sigmoidoscopy provides direct visualization of the distal portion of the colorectum and 
the opportunity to biopsy and/or remove polyps. Bowel preparation consists of enemas with or 
without oral magnesium citrate, and no sedation is required. Four long-term (11–17 years) 
randomized controlled trials compared effects of flexible sigmoidoscopy with no screening.24-27 
A meta-analysis (n=458,002) found that flexible sigmoidoscopy decreased CRC morality by 
27% (95% CI, 18%–34%), compared to no screening at 11–12 years of follow up, in intention to 
screen analyses (Table 1).12 Moreover, CRC incidence was reduced by 21% ( 95% CI, 15%–
25%) with flexible sigmoidoscopy compared with no screening. In per-protocol analyses, 
flexible sigmoidoscopy resulted in 38%–43% reductions in CRC mortality and 31%–33% 
reductions in CRC incidence.27, 28 
The reduction in CRC mortality and incidence was significant for only distal CRC, with 
an incidence rate ratio of 0.63 (95% CI, 0.49–0.84) compared with 0.90 ( 95% CI, 0.77–1.04) for 
proximal CRC.12 This mortality reduction benefit appears to be greater for men than women,29 
possibly due to differences in neoplasia distribution. Flexible sigmoidoscopy is recommended 
every 5 years.  
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Colonoscopy, which is indicated after other less-invasive tests are positive, can also be 
used for primary screening. Colonoscopy requires dietary modification and administration of a 
purgative preparation. Most individuals undergo colonoscopy with sedation, requiring the 
assistance of someone to transport them after the procedure. No randomized trials have been 
completed that evaluated the efficacy of colonoscopy, but the NordICC study, a randomized trial 
that is underway in Northern Europe, is comparing colonoscopy to no organized screening.30, 31 
Cohort and case–control studies found an association between lower endoscopy and reduced 
CRC mortality and incidence (Table 1).32-42 A large prospective cohort study of nearly 89,000 
nurses and other health care professionals found that, over 24 years of follow up, colonoscopy 
was associated with a 68% reduction (95% CI, 55%–76%) in CRC-specific mortality compared 
with no exposure to colonoscopy.37 Individuals who underwent colonoscopy with polypectomy 
were found to have a 43% reduction in CRC incidence compared to those with no lower 
endoscopy.  
 Although CRC screening tests are often compared to colonoscopy, colonoscopy can miss 
lesions as well. In studies comparing colonoscopy to CTC, or to colonoscopy enhanced by 
knowledge of CTC results, the estimated per-person sensitivities ranged from 89.1% to 94.7% 
for adenomas ≥10 mm and from 74.6% to 92.8% for adenomas ≥6 mm (Table 2).12 A systematic 
review of tandem colonoscopy studies reported miss rates of 26% for adenomas (95% CI, 23%–
30%), 9% for advanced adenomas (95% CI, 4%–16%), and 27% for serrated polyps ( 95% CI, 
16%–40%).43 Screening colonoscopy is recommended every 10 years. 
CTC also allows for visualization of the entire colorectum. CTC is typically performed 
after administration of a bowel preparation and/or an agent to radiographically tag stool for 
digital subtraction. CO2 insufflation is achieved via a rectal balloon catheter. There are no studies 
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evaluating the effect of CTC on CRC incidence or mortality. In a meta-analysis that compared 
the effects of CTC with those of colonoscopy, the per-person sensitivity of CTC for adenomas 
≥10 mm ranged from 66.7% to 93.5%, with specificity values ranging from 96.0% to 97.9% 
(Table 2).12 For adenomas ≥6 mm, sensitivity ranged from 72.7% to 98.0%, with specificity 
values ranging from 79.6% to 93.1%. In a randomized controlled trial that compared CTC with 
colonoscopy for population screening, detection of high-risk sessile serrated lesions (dysplastic 
and/or ≥10 mm) was significantly lower with CTC (0.8%) than with colonoscopy (4.3%).44 CTC 
is mostly used after incomplete colonoscopy and for individuals at high risk for colonoscopy, but 
some centers use it for primary screening. The risk of radiation associated with contemporary 
CTC protocols is probably minimal, but the balance of benefit vs harm of detecting extracolonic 
findings remains uncertain. CTC is recommended every 5 years.  
The US Food and Drug Administration (FDA) approved a blood-based test that detects 
circulating methylated DNA encoding septin 9, a plasma marker of CRC. This test is only 
approved for individuals who have been offered and declined the screening tests recommended 
by the US Preventive Services Task Force (USPSTF).45 In a large prospective study, this test 
detected CRC with 48.2% sensitivity and 91.5% specificity.46 When archived samples were 
retested with a next-generation assay, it identified early-stage CRC with 59% sensitivity and 
later-stage CRC with 87% sensitivity, and specificity values of 79%.47 A meta-analysis of studies 
of this assay found a pooled sensitivity of 67% and specificity of 89% for detection of CRC.48 
Capsule colonoscopy involves ingestion of a large pill-sized camera that records images 
during its transit through the intestine. Highly effective bowel preparation is required, typically 
involving use of booster doses and/or a prokinetic agent. This procedure is not recommended for 
screening by the USPSTF, or approved by the FDA as a first-line screening test, though it is 
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approved for patients with incomplete colonoscopy despite adequate bowel preparation. Studies 
of capsule colonoscopy are limited to test-characteristic studies compared to colonoscopy. In a 
study of 695 individuals who underwent capsule colonoscopy followed by standard colonoscopy, 
the per-person sensitivity for cancer was 100% (in 4 patients), while the per-person sensitivities 
were 92% and 88% for adenomas ≥10 mm and ≥6 mm adenomas, respectively, with specificity 
of 95% and 82% for ≥10 mm and ≥6 mm adenomas, respectively.49 As with CTC, sessile 
serrated polyps were difficult to detect, accounting for 26% of false-negative results in patients 
with polyps ≥6 mm.  
 
Effectiveness studies vs test-characteristic studies 
Comparisons of colonoscopy’s benefits in cohort studies to the intent to screen results of gFOBT 
or flexible sigmoidoscopy in randomized trials are compromised by selection bias. Individuals 
who undergo colonoscopy have, by definition, perfect screening adherence. Studies that compare 
one-time application of screening tests to colonoscopy (mt-sDNA and FIT) do not reflect the 
real-world implementation of these tests. For example, no data are available on the programmatic 
application of annual FIT compared with every 3-year screening with the mt-sDNA test. 
Modeling studies have attempted to address these questions, but are limited by the absence of 
actual implementation data. 
 
Programmatic Issues 
The effectiveness of screening depends not only on the screening test characteristics, but also on 
patient adherence. Worldwide, organized CRC screening programs are proliferating. Although 
most CRC screening in the US is opportunistic, there are a few examples of organized screening 
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(such as Kaiser Permanente and the Veterans Health Administration). In opportunistic screening, 
tests that are performed infrequently (such as colonoscopy), and therefore require fewer 
reminders, gain appeal. In organized screening, tools to identify screen-eligible individuals (such 
as clinical reminders in the electronic health record) and to promote adherence, such as 
navigators, are required. Through the use of direct to patient annual FIT outreach, with 
colonoscopy as a secondary option, Kaiser Permanente of Northern California increased the 
proportion of individuals up to date with screening from 38.9% to 82.7% over 15 years.50 This 
was associated with a 25.5% reduction in annual CRC incidence and a 52.4% reduction in CRC 
mortality as well as an increase in the rate of colonoscopy after a positive FIT from 41.1% to 
83.1%.  
Test specificity has important implications for programmatic screening. Tests with lower 
specificity will result in a larger number of false positives, leading to additional diagnostic 
evaluations with their risks and costs. It remains to be seen how providers and patients will deal 
with normal colonoscopies after abnormal non-invasive screening, as some have advocated 
repeat screening earlier than would otherwise be recommended.51, 52  
 
Comparative Effectiveness 
We must use caution in comparing results of studies of different screening modalities because of 
differences among study populations and in the adherence rates achieved with specific 
implementation strategies. No long-term comparisons between screening alternatives have been 
completed, but 4 large randomized controlled trials are underway.30, 53-55 The Veteran 
Administration’s CONFIRM trial and the Spanish COLONPREV trial are comparing one-time 
colonoscopy vs annual or biennial FIT, respectively, and the Swedish SCREESCO trial is comparing 
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one-time colonoscopy vs 2 rounds of FIT vs a no intervention control. The NordICC trial is 
comparing colonoscopy vs no organized screening. 
 No trial will ever be conducted to compare all screening options against each other. Even if 
such a trial were ever launched, how would we evaluate a new, promising test? A consensus has 
emerged that, building on the effectiveness of screening demonstrated in randomized trials of 
gFOBT and sigmoidoscopy, it is reasonable to compare CRC screening tests to each other based on 
their test performance characteristics, including sensitivity for early-stage CRC and advanced 
precancerous lesions, and specificity.56  
 Available comparative data include results from the first rounds of testing in randomized 
trials, with lesion detection as a surrogate marker. Computerized models have been developed to 
make long-term projections of clinical outcomes (CRC cases and deaths prevented, and life-years 
gained).  
 
Single-round vs programmatic screening and the importance of participation 
In the first-round of the COLONPREV study, participation rates in the FIT and colonoscopy groups 
were 34.2% and 24.6%, respectively.54 In those actually screened, detection rates for FIT vs 
colonoscopy were 0.3% vs 0.5% for CRC and 2.4% vs 9.7% for advanced adenoma. However, in the 
intent to screen analysis, which accounts for the differential participation, detection rates for FIT vs 
colonoscopy were 0.1% vs 0.1% (not significant) for CRC and 0.9% vs 1.9% (significant) for 
advanced adenoma. It is anticipated that the programmatic effectiveness of the FIT intervention will 
improve over subsequent cycles, as FIT is offered again every 2 years and more CRCs and advanced 
adenomas are detected. 
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In a randomized trial of CTC vs colonoscopy in The Netherlands, participation rates in the 
CTC and colonoscopy groups were 34% and 22%, respectively.57 In those actually screened, 
detection rates for CTC vs colonoscopy were 0.5% vs 0.5% (not significant) for CRC and 5.6% vs 
8.2% (significant) for advanced adenoma.  
Longitudinal participation patterns through multiple cycles of fecal testing have been 
described.58, 59 These include consistent screeners; intermittent screeners with late entry, drop out, or 
intermittent participation; and consistent non-responders. The participation patterns attained in the 
ongoing prospective trials will have implications for the interpretation of the trials’ results. FIT is 
being offered yearly in CONFIRM and every 2 years in COLONPREV over 10 years, and 2 years 
apart for only 2 rounds in SCREESCO; furthermore, the FIT arms include programmatic invitations 
every cycle, while colonoscopy is being offered only once, although in CONFIRM, the follow up of 
those who fail to complete their colonoscopy is left to local policy, allowing for heterogeneity in 
subsequent efforts to enhance adherence.53 In opportunistic screening, it is common for patients to 
present for colonoscopy after several unsuccessful recommendations by primary care providers to 
screen, sometimes over years. Repeated invitations might yield higher cumulative participation rates 
than once-only invitations. Interpretations of the intention-to-screen results in the ongoing trials will 
need to consider whether the participation patterns observed, which reflect the specific study 
populations and invitation protocols, can be generalized to other settings.  
 
Estimating long-term comparative effectiveness with modeling 
Multiple CRC screening models have been developed worldwide to address questions that are 
unlikely to be answered directly by clinical trials. In the US, 3 models from the National Cancer 
Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET) consortium have 
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informed the USPSTF60, 61 and American Cancer Society (ACS) screening guidelines.62-64  
Table 3 shows the long-term effects of screening on CRC incidence and mortality that is 
projected for 5 screening modalities, with optimal participation over time, by the 3 CISNET 
models61, 65 and a fourth model that has been validated against prospective trials of gFOBT and 
sigmoidoscopy.66, 67 The estimated CRC incidence reductions with annual FIT and colonoscopy, for 
instance, range from 47% to 72% and from 62% to 88%, respectively; the estimated CRC mortality 
reductions with annual FIT and colonoscopy range from 72% to 81% and from 77% to 90%, 
respectively. In general, models tend to predict that, among those participating consistently in 
screening, colonoscopy every 10 years yields the largest reductions in CRC incidence and mortality, 
but the programmatic effects of other modalities approaches that of colonoscopy (see Table 3). As 
expected, and desired, models’ predictions of comparative effectiveness are greatly affected if 
differential participation patterns are assumed between strategies.  
 
Cost Effectiveness 
Three systematic reviews (published in 2000, 2010, and 2016), covering 1993–2016,68-70 assessed the 
multiple cost-effectiveness analyses of CRC screening that have been performed worldwide, 
including regional epidemiology data and costs (Table 4). These analyses tend to focus on high-
income countries, reflecting the availability of resources and the relative burden of disease and 
public health priorities vs low-income countries.71, 72 
 The apparently small average gains in discounted life-years per person predicted by the 
models (Table 4) reflect relatively large gains in undiscounted life-years by the small percentage of 
people who benefit by avoiding CRC-associated death, divided by the entire population.73 Is it 
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reasonable for models to predict that CRC screening prolongs life? An insightful meta-analysis of 
screening sigmoidoscopy randomized trials reported a relative risk of all-cause mortality of 0.975 for 
screening vs control.74 It is therefore reasonable for modeling studies to project reductions in overall 
mortality even if individual trials are not powered to detect it. 
There are four principal conclusions. Compared with no screening, all screening modalities 
are generally predicted to be cost effective (see Table 4).68-70 As the costs of treatments for advanced 
CRC have increased, with proportionately modest gains in survival, the cost effectiveness of CRC 
screening has improved, with many strategies becoming cost-saving in the US.68-70, 75, 76 When 
participation levels are the same among strategies, there is no uniformly favored strategy.68-70 
Established strategies are generally favored over emerging strategies such as CTC and mt-sDNA 
tests.69, 70 
In a analysis of the effects of participation rates and program costs, opportunistic FIT was 
cost saving.67 An organized FIT program with higher participation rates was substantially more 
effective and was highly cost effective, but was no longer cost saving, due to the additional program 
costs, including infrastructure and outreach, required to improve adherence.67 Given the high cost of 
the mt-sDNA test compared with FIT, the patient support program included with the mt-sDNA test 
would need to yield high participation levels, relative to FIT, for mt-sDNA test to be competitive.67 
A recent analysis focusing on the latest ACS CRC screening recommendation concluded that 
screening initiation at age 45 years vs 50 years is likely to be cost effective, with costs/QALY gained 
of $33,900 for colonoscopy and $7700 for FIT.66 However, substantially greater benefits and also 
cost savings could be realized if the same resources could instead be used to improve participation 
among unscreened older persons.66 It remains to be seen whether we can screen younger people and 
improve screening rates in older people, or whether we face resource constraints and trade-offs.  
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The total budget effects of CRC screening depends on a screening program’s costs balanced 
against CRC treatment costs averted, costs from an organized population management program, and 
the phase of implementation (initial launch vs steady state), because it can take years for screening 
programs to realize savings in averted CRC care. Program costs can be considerable.77, 78 In the US, 
navigation for 1-time screening colonoscopy may be cost saving, and navigation for a program of 
repeated colonoscopic screening is estimated to be highly cost effective.79 A modeling study 
indicated that screening at ages 50–64 under commercial insurance in the US yields substantial 
clinical and economic benefits that accrue primarily at ages ≥ 65 under Medicare.80  
 
Harms of Screening 
The shadow of the Telemark sigmoidoscopy study hung over the early years of CRC screening.81 
In that study of modest sample size, screening decreased CRC incidence, but higher overall 
mortality was observed in the screening group (14%) vs unscreened patients (9%). More recent, 
larger, randomized trials have provided reassurance that the Telemark study results were an 
aberration.74 
 The principal harms of CRC screening relate to the potential complications of lower 
endoscopy. A recent systematic review reported pooled risk estimates of 4% for perforation and 
8% for major hemorrhage per 10,000 screening colonoscopies.12 The risks with polypectomy are 
higher.82 In a population-based study from California, the rates of myocardial infarction, stroke, 
and serious pulmonary events after colonoscopy were low and no higher than after low-risk 
comparator procedures, so they are unlikely to affect the benefit-to-risk balance of 
colonoscopy.82 
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Emerging Screening Strategies 
Changes to screening paradigms could come from the development of new tests. Blood tests are 
widely adopted, evidenced by the frequent use of the prostate-specific antigen test to detect prostate 
cancer, despite the unenthusiastic recommendation from the USPSTF.83 In addition, disruptive 
enhancements could be developed for established strategies, such as colonoscopy or FIT. Finally, 
new visualization strategies, including next-generation capsule endoscopy, could be used. 
Circulating tumor DNA (ctDNA), also called cell-free DNA or liquid biopsy,84 are sequences 
of DNA detected in the circulation derived from tumor cells undergoing apoptosis. Fragments of 
DNA with variants or mutations found in cancer cells can be specific markers of tumors. However, 
the number of mutant DNA fragments found in plasma varies among tumor types.85, 86 Levels of 
ctDNA can indicate the overall tumor burden85, 87, 88 (higher levels correlating with larger or more 
advanced tumors), but some patients with advanced tumors do not have detectable ctDNA.85, 89 
Moreover, for any specific tumor type, it is not clear why some patients have detectable ctDNA and 
others do not. The number of ctDNA fragments can be as low as 1 single mutant fragment per 1 ml 
plasma, so digital genomic technology with next-generation sequencing and massive parallel 
sequencing are used to amplify the mutant ctDNA fragments. These systems can be used to 
determine whether the mutated fragment of DNA came from a cancer cell or was a random error of 
DNA polymerase in a normal cell.84, 90  
Circulating tumor cells are intact tumor cells that can be purified from blood using 
physicochemical or cell surface molecules. Using a highly sensitive technique for ctDNA 
quantification and to avoid technical issues related to purification of circulating tumor cells, 
researchers found no samples to contain circulating tumor cells but no ctDNA.85 However, in many 
samples, ctDNA could be detected when circulating tumor cells were absent.85 Tests for ctDNA are 
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therefore more promising for identification of patients with CRC.  
For persons with a diagnosis of cancer, ctDNA analysis might be used to determine their 
prognoses or in surveillance for recurrence. In patients with stage 2 CRC, detection of ctDNA after 
surgery increased risk of recurrence 18-fold compared with no detection of DNA.91 The assay for 
ctDNA also more accurately identified patients with stage 2 CRC who are candidates for adjuvant 
chemotherapy than did clinical characteristics.92 Increased levels of ctDNA preceded increased levels 
of carcinoembryonic antigen.92 ctDNA also provided clues into the mechanisms underlying 
resistance to EGFR blockade in patients who objectively responded to therapy but subsequently 
relapsed.85  
Researchers identified a collection of 61 mutations or amplifications in 16 genes that can be 
used to screen for 8 cancers, including ovary, liver, stomach, pancreas, esophagus, colorectal, lung, 
or breast (the CancerSEEK panel).86 Because the test for ctDNA does not detect most early-stage 
tumors with a high level of sensitivity, researchers included in the test assays for 8 protein 
biomarkers that can be detected in blood. The threshold for a positive result was set high for each 
protein marker, to maximize specificity and avoid false-positive results, in recognition that each 
protein increases sensitivity by a small amount. In a case–control study of 1005 patients with stage 
1–3 tumors and 812 individuals without cancer (controls), this test identified patients with cancer 
with 70% sensitivity and >99% specificity; results ranged from 98% sensitivity in detection of 
ovarian and hepatocellular cancers to 33% in detection of breast cancer. This test identified patients 
with CRC with 66% sensitivity.86 
These mutations and proteins are markers of several tumor types, so it is not clear how to 
follow up patients with positive results from this test. A machine-learning algorithm was able to 
localize the source of the cancer to 1 of 2 anatomic sites in a median of 83% of patients86. A 
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prospective study is underway at the Geisinger Health Center, in collaboration with Johns Hopkins 
University, to evaluate levels of ctDNA and proteins in blood samples from 10,000 women, 65–75 
years old (the DETECT trial). Subjects with 2 consecutive positive test results will be evaluated for 
the predicted site of neoplasia and undergo imaging analyses (https://www.geisinger.org/sites/detect-
study). Subjects will be followed for clinical signs of cancer for at least 2 years.  
 
Epigenetic markers 
Epigenetic changes are alterations that affect expression of mRNA or protein but not DNA 
sequences. Epigenetic changes include alterations in DNA methylation (increases or decreases at 
certain loci), in histones, and in translation of mRNAs via interactions with non-coding RNAs.93 
Epigenetic markers could be used to predict disease progression or response to treatment, or in 
screening. 
Changes in DNA methylation can alter gene expression. The average CRC cell has hundreds 
to thousands of abnormally methylated genes,93 based on methylome analyses. Some of these alter 
transcription of genes that contribute to tumorigenesis or tumor progression.94 A panel of markers 
might someday be used in screening for CRC. Although markers of  abnormal methylation patterns 
have been associated with transformation and tumor development, methylation changes are heritable 
and can accumulate in aging and inflammatory conditions, compromising specificity.  
An assay to detect changes in methylation at the septin9 gene in plasma samples has been 
approved by the FDA for CRC screening. The assay identifies patients with CRC with approximately 
70% sensitivity, with a 10%–20% false-positive rate, so it may have limited practical utility.  
Modification in histone proteins affects the 3-dimsional structure of nucleosomes and 
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transcription of multiple genes. Technical limitations in assessing histone modifications limit our 
ability to determine whether histone modifications can be used to identify cancer cells. Exploratory 
studies have been performed,93, 95 but further research is needed.  
Approximately 80% of the genome is transcribed into non-coding RNAs, which include 
microRNAs and long non-coding RNAs.93 These RNA molecules are not transcribed into proteins, 
but regulate gene expression at the transcriptional and post-transcriptional level. Changes in miRNA 
levels and activities have been observed in cancer cells. MicroRNAs levels might be used as markers 
of cancer, due to their stability, small size, and hairpin-loop structure that protects them from 
degradation. It is easy to extract microRNAs from specimens including blood, stool, and saliva, and 
microRNAs are secreted by tumors into the circulation and gastrointestinal tract.93, 96 However, lack 
of standardization in measurement has hampered their practical application. Changes in levels of 
individual microRNAs and panels of miRNAs have been associated with different cancers, but these 
assays are not ready for use in the clinic .97  
Levels of specific proteins have also been associated with cancer,97 but no 1 protein or panel 
of proteins identifies patients with cancer with sufficient levels of sensitivity for clinical use. 
Combination assays for specific proteins and ctDNA might increase the sensitivity of tumor 
detection, with higher levels of specificity.  
Volatile organic compounds (VOCs) are metabolites that can be detected by smell. VOC 
patterns are altered in stool, urine, and breath samples of patients with cancer, and a specially trained 
Labrador retriever was able identify patients with CRC.98,99 VOCs have been explored as biomarkers 
of CRC in small, case–control studies.100 In a gas mixture, VOCs are analyzed by gas 
chromatography-mass spectrometry, and researchers have developed a sensor array called an 
electronic nose. With a pattern detector, the individual components cannot be determined.99, 100 
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Studies are needed to validate VOCs as biomarkers of CRC, as well as to standardize analytic 
techniques, determine reproducibility of assays, and identify potential confounding factors such as 
diet, microbiome, and medication use. 
 
Improving FIT, colonoscopy and capsules 
The FIT is used in CRC screening programs worldwide. Most FITs approved by the FDA are 
qualitative, but quantitative FITs have well-documented merits.21 It is possible to combine 
quantitative FITs with basic demographic information to create a smarter FIT, with greater 
predictive power for advanced neoplasia.101 The combination of fecal hemoglobin concentration 
and patient age and sex identified patients with advanced neoplasia with positive-predictive 
values that ranged from 21% to 76% and an 11-fold variation in advanced neoplasia risk across 
categories.102 Such approaches are advantageous because they capitalize on existing screening 
infrastructures, and allow prioritization of referrals to colonoscopy.  
 Colonoscopy is the final common pathway of all CRC screening tests, and arguably the 
most effective single-application method for preventing CRC. Its major drawbacks are its 
operator dependency, reflected in the inverse association between adenoma detection rate and 
post-colonoscopy CRC risk, its significant burden to patients, and its high cost.103, 104 Strategies 
to improve colonoscopy include adjuncts to increase mucosal exposure (cap, Endocuff, 
AmplifEye, EndoRings, G-EYE), technologies that enhance imaging (dye-based 
chromoendoscopy and electronic chromoendoscopy, including NBI, FICE, iScan, BLI), wider 
viewing angles (FUSE, Saneso 360◦ system), and non-device techniques (water-based 
colonoscopy, dynamic position changes, second look in the proximal colon). Most mucosal 
exposure devices and chromoendoscopy have overall positive effects on neoplasia detection.105, 
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 A new methylene blue-MMX oral preparation that is pending FDA approval might offer 
practical advantages over traditional dye-based chromoendoscopy.107 It is not clear whether these 
adjuncts are more helpful to low-level or high-level detectors, or whether they offer significant 
advantages over non-device interventions, such as second look in the right colon or water-based 
methods.106, 108 To optimize CRC screening, we need to focus on improving performance in low-
level detectors, because lower detection provides less protection against CRC, and because 
improved detection of diminutive lesions by high-level detectors is of uncertain clinical benefit.  
Available colon capsules are passive viewing devices with applications that are limited to 
patients with incomplete colonoscopy or who decline other screening tests.109 The required 
arduous colon preparation is a limitation. However, the technology is advancing rapidly, 
including magnetically controlled or self-propelled capsules.110 Reliable optical biopsy and 
therapeutic capabilities could change paradigms. 
 
Future Directions 
The maximum preventable fraction of CRC cases and deaths that screening can achieve is probably 
high, but it is not clear how high (Figure 1A). In theory, frequent non-invasive monitoring could 
detect most incipient CRCs, or at worst, CRC at an early stage. On the other hand, accurate 
identification of low-risk colorectums and successful clearance of all relevant neoplasia even in high-
risk colorectums could allow for relatively infrequent re-testing, given the long dwell-times from 
polyp to CRC. 
 The demise of screening colonoscopy has been predicted almost from its inception. It has not 
happened. This could change quickly depending on innovations around non-invasive alternatives, 
and how well they are accepted by patients. All CRC screening roads ultimately lead to colonoscopy, 
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and colonoscopies prevent CRC because they include polypectomy, so it is the responsibility of 
endoscopists to perform colonoscopies with skill (Figure 1A)—whether during primary screening, 
follow-up of non-invasive screening test results, surveillance, or symptom evaluation.  
Artificial intelligence (AI) could revolutionize screening in general, and endoscopy 
specifically.111, 112 Computer-aided detection and histologic diagnosis systems are available and 
have shown promising results.113-116 However, adequate mucosal exposure and lesion resection 
will remain operator dependent. The most immediate goal is developing a real-time colonoscopy 
AI system that combines high detection sensitivity, high characterization accuracy, and fast 
processing time. However, AI-assisted colonoscopy could go further—if AI systems could 
reliably rate the adequacy of inspection and lesion resection, and provide real-time feedback to 
ensure adequate performance (incompletely visualized segment—recommend re-examination; 
residual polyp at margin—recommend resection and re-examination), it might be possible to 
certify a colonoscopy as: excellent visualization, all relevant lesions detected and removed. This 
might provide confidence to prolong screening and surveillance intervals. Such a paradigm could 
resolve the conundrum of the high polyp detector, in which patients who are presumably at low 
CRC risk after multiple successful polypectomies are surveyed intensively unnecessarily, 
precisely because of polyp multiplicity.  
Regardless of screening strategy, patient participation will always be a key determinant 
of success. This is a social and behavioral challenge, as screening is a personal choice that is 
ideally based on informed decision making. Organized programs have advantages over 
opportunistic screening. However, the full potential benefit of outreach, navigation, and rapidly 
evolving digital innovations, such as smart phone applications, have not yet been realized. In the 
US, a national CRC screening program could be the next big step, but that is a major challenge 
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given the healthcare system. The effects of commercial incentives on screening participation, 
such as the aggressive direct to consumer and primary-care, physician-centered campaigns 
promoting the mt-sDNA test, are not completely clear. We will need to determine the effects of 
such incentives on test choice, in addition to considerations based on test performance 
characteristics, interval, cost and acceptability by patients. 
 There is evidence for overutilization and underutilization of screening and surveillance. 
Risk stratification and personalized screening could optimize outcomes while making the best 
use of resources.101 Although it is not clear whether other guidelines will follow the ACS 
recommendation to lower the CRC screening initiation age to 45 years, the recommendation 
could be replaced by a sophisticated risk-stratification approach that is based on multiple factors. 
For many older patients, the risks of screening and surveillance outweigh the benefits, but 
screening of some older patients might be warranted.  
CRC is a prime example of a public health success. We should be proud of the research 
that has brought us here, and of what we can do for the population today. As we strive to do 
better, we must not compromise the gains that can be achieved with current paradigms. We can 
envision sophisticated strategies for risk stratification and personalization, and complex quality 
metrics beyond the adenoma detect rate, as well as hybrid screening strategies that change over 
the course of life. However, efficacy in the ideal setting with optimal implementation might be 
different from effectiveness in the messy real world (see Figure 1). Highly efficacious strategies 
that are impractical to implement could harm screening participation, resulting in lower overall 
impact on CRC outcomes.  On the other hand, sophisticated new strategies that harness 
technological innovation and the growing understanding of factors motivating human behavior 
could be revolutionary. 
 25
Figure 1. Considerations for CRC screening.  
1a) Even with new screening tests, colonoscopy with polypectomy is likely to remain the 
cornerstone of CRC prevention. We must ensure skillful inspection, lesion characterization, and 
lesion removal, whether in primary screening, follow-up of non-invasive screening test results, 
surveillance, or symptom evaluation. 1b) Risk-stratification and personalization, additional 
quality metrics beyond the adenoma detection rate, or other innovations such as hybrid screening 
programs that coalesce to produce increasingly sophisticated and effective screening strategies 
must avoid excessive complexity, resource-consumption, and other limitations that could 
decrease screening participation and inadvertently harm CRC control efforts. 1c) New strategies 
that are efficacious and practical to implement could revolutionize CRC screening. 
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Table 1. Effects of Screening on CRC Incidence and Mortality 
Screening Test Evidence Sources Reduction in 
CRC Incidence 
Reduction in 
CRC Mortality 
Reduction in 
Overall Mortality 
stool-based tests     
gFOBT7-12  randomized controlled trials 17%–20% 9%–22% no benefit 
demonstrated 
FIT17-19 observational studies, 
test characteristic studies 
10% 22%–62% 
 
unknown 
FIT-DNA (mt-sDNA test) test characteristic studies, compared 
to fit and colonoscopy 
unknown unknown unknown 
direct visualization tests     
flexible sigmoidoscopy24-27, 74  randomized controlled trials intent to treat: 
27% (17%–23%); 
per protocol: 
31%–33% 
intent to treat:  
21% (22%–
31%); 
per protocol: 
38%–43% 
2%–4% in 
individual 
studies; 2.5% in 
meta-analysis 
colonoscopy32-42 observational studies cohort: 40%–
69% 
case–control: 
31%–91% 
cohort: 29%-
88% 
case–control: 
60%–70% 
unknown 
CTC test characteristic studies unknown unknown unknown 
gFOBT guaiac fecal occult blood test, FIT fecal immunochemical test, mt-sDNA multitarget stool DNA, CT computed tomography 
Note: due to differences in study methodologies, cells cannot be directly compared. Randomized controlled trials generally report 
results on an intent to screen basis whereas observational studies generally compare persons who underwent screening with persons 
who did not, raising concerns about self-selection bias. 
 
 
  
Table 2. Performance of Modalities Included in USPSTF Recommendations 
   Sensitivity Specificity 
Screening Test Programmatic 
Frequency 
Colorectal 
Cancer  
Advanced 
Adenoma 
Advanced 
Serrated 
Polyp 
Non-
advanced 
Adenoma 
Non-
advanced 
Serrated 
Polyp 
(1 minus 
positivity 
rate in 
normal 
colon) 
stool-based tests        
gFOBT14, 15 annually 62%-79%     87%-96% 
FIT20 annually 79% 23.8% 5% 7.6%  94% 
FIT-DNA (mt-sDNA test) 23 every 3 years any, 
92.3%; 
stages 
1–3, 
93.3% 
42.4% 
(includes 
large 
sessile 
serrated 
polyp) 
42.4% 17.2%  86.6 
direct visualization tests        
flexible sigmoidoscopy every 5 y 
(or 10 y if 
combined with 
annual FIT) 
within its reach, may be similar to colonoscopy 
colonoscopy12, 117-124 every 10 years  89.1%–
94.7% 
(size cutoff 
10mm) 
range of 
detection 
rates: 
0.5-1.5% 
74.6%–
92.8% 
(size 
cutoff 
6mm)  
range of 
detection 
rates: 
6%–20% 
 
CTC 12, 125 every 5 years  89% 
(82%–
96%) 
(size cutoff 
10mm) 
 
 86% 
(78%–
95%) 
(size 
cutoff 
6mm) 
3% for ≥10 
mm 
adenoma:  
94% 
(89%–
100%); 
for ≥6 mm 
adenoma: 
88% 
(82%–
94%) 
serology tests        
methylated septin 9 gene **46 not defined any 
48.2%; 
stages 
1–3 
45.1% 
11.2%    91.5% 
Note: Considerations beyond test performance that can aid clinicians make decisions, including test attributes, patient requirements, 
and interpretation of test results, have been detailed recently.126  
** In the USPSTF recommendation statement, the table on characteristics of colorectal cancer screening strategies includes the 
footnote “Although a serology test to detect methylated SEPT9 DNA was included in the systematic evidence review, this screening 
method currently has limited evidence evaluating its use (a single published test characteristic study met inclusion criteria, which 
found it had a sensitivity to detect colorectal cancer of <50%). It is therefore not included in this table.” 
 
  
Table 3. Projected Long-term Comparative Effectiveness of CRC Screening Strategies With Optimal Participation 
 
  Colorectal Cancer Incidence, 
% Reduction vs No Screening 
Colorectal Cancer Mortality, 
% Reduction vs No Screening 
 
SimCRC
61, 65
 
MISCAN
61, 65
 
CRC-
SPIN61, 65 
Ladabaum 
et al. 66, 67 
SimCRC
61, 65
 
MISCAN
61, 65
 
CRC-
SPIN61, 65 
Ladabaum et 
al.66, 67 
Colonoscopy every 10 years, 
ages 50–75 years 81% 62% 88% 70% 87% 79% 90% 77% 
FIT yearly, ages 50–75 years 67% 47% 72% 57% 81% 72% 81% 72% 
mt-sDNA every 3 years, 
ages 50–75 years 63% 43% 68% 52% 78% 68% 76% 67% 
CT colonography every 5 
years, ages 50–75 years 77% 51% 78% 67% 85% 72% 82% 77% 
Sigmoidoscopy every 5 
years, ages 50–75 years 68% 56% 59% 44% 74% 72% 62% 49% 
SimCRC, Simulation Model of Colorectal Cancer; MISCAN, Microsimulation Screening Analysis for Colorectal Cancer; CRC-SPIN, 
Colorectal Cancer Simulated Population model for Incidence and Natural history. 
SimCRC, MISCAN and CRC-SPIN are part of the National Cancer Institute’s Cancer Intervention and Surveillance Modeling 
Network (CISNET) consortium. 
CT computed tomography, FIT fecal immunochemical test, mt-sDNA multitarget stool DNA 
  
Table 4. Cost Effectiveness of CRC Screening strategies vs No Screening      
 
Annual 
gFOBT 
Biennial 
gFOBT Annual FIT Biennial FIT 
FS every 5 
years 
Colonoscopy 
every 10 
years 
CT 
colonography 
every 5 years 
mt-sDNA 
test every 3 
years 
Systematic Review 2010-2017, 33 studies (17 Europe, 11 North America, 4 Asia, 1 Australia), 2016 $67, 70 
LY gained 0.01-0.12 0.01-0.05 0.01-0.15 0.01-0.10 0.02-0.14 0.02-0.18 -- -- 
QALY 
gained 0.07-0.49 0.01-0.32 0.01-0.80 0.01-0.70 0.01-0.07 0.02-0.22 -- -- 
Cost/LY 
gained 
CS - $4000; 
[$50,000] 
CS - $3000; 
[$45,000] 
CS - $9000; 
[$24,000] 
CS - $4000; 
[$24,000] 
CS - $7000; 
[$67,000] 
CS - 
$27,000; 
[$52,000] 
CS - $16,000 $9,000 - $11,000 
Cost/QALY 
gained 
CS - 
$15,000 CS - $6,000 
CS - $5,000; 
[$33,000] CS - $7000 
CS - $8000; 
[$45,000] 
CS - 
$15,000; 
[$40,000] 
$3000 - 
$11,000; 
[$59,000] 
$15,000 - 
$30,000 
Review 1993-2009, 32 unique models (10 Europe, 14 North America, 5 Asia, 3 Australia), 2010 $69 
LY or 
QALY 
gained 
0.01-0.16 0.01-0.03 -- 0.01-0.11 0.02-0.18 -- -- 
Cost/LY or 
Cost/QALY 
gained 
CS - 
$26,000; 
[$53,000] 
$3000-
$16,000 CS - $26,000 
CS - 
$30,000; 
[$57,000] 
CS - $32,000 CS - $36,000 $600 - $32,000 
Systematic Review for USPSTF 1993-2001, 7 studies (7 US), 2000 $68 
Cost/LY 
gained 
$6000-
$18,000 -- -- 
$12,000-
$39,000 
$9,000-
$22,000 -- -- 
CS, cost saving; FS, flexible sigmoidoscopy; LY, life-year; USPSTF, US Preventive Services Task Force; QALY, quality-adjusted 
life-year. 
Notes: Ranges reported in published studies are shown; single values judged to be outliers at the high end of the range are shown 
separately in brackets. Costs are rounded to nearest $1000, and LYs and QALYs are rounded to nearest 0.01, and all reflect annual 
discounting, usually at rates 3%–5%. 
All potentially relevant published studies were included in the systematic reviews. Some studies reported life-years, and some quality-
adjusted life-years, so both outcomes are shown. 
All currencies were converted to US dollars and updated to a given year, which differed in each review. 
Columns are not directly comparable to each other because not all studies in a review contributed to every cell or explicitly compared 
all strategies to each other. 
 

